# US 2010/0143478 A1 · Treatment of inflammation and the complement and kinin cascades in a patient, particularly in chronic ulcerous skin lesions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0143478 A1
- Document ID: US20100143478A1
- Status: Published application
- Kind: A1
- Application number: 12/523,715
- Filed: 2008-01-17
- Published: 2010-06-10
- Earliest claimed: 2007-01-17
- Inventors: Hugh Semple Munro
- Web page: https://patentgrep.com/patent/US20100143478A1

## CPC

- A61L 26/008: {Hydrogels or hydrocolloids}
- A61L 15/60: Liquid-swellable gel-forming materials, e.g. super-absorbents
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides methods of inhibiting inflammation and/or the complement cascade and/or the kinin cascade in a human or non-human animal patient, particularly in a wound (for example, a chronic ulcerous skin lesion) in a human or non-human mammal (particularly a human). The affected location of the patient is contacted with a hydrogel composition comprising a hydrophilic polymer carrying multiple pendant sulphonyl groups, optionally with multiple pendant carboxylic groups, on each polymer molecule.

## Claims

### Claim 1

A method of inhibiting inflammation and/or the complement cascade and/or the kinin cascade in a human or non-human animal patient, comprising contacting an affected location of the patient's body for an effective period of time with a hydrogel composition comprising a hydrophilic polymer carrying multiple pendant sulphonyl groups, optionally with multiple pendant carboxylic groups, on each polymer molecule.

### Claim 2 (depends on 1)

A method according to claim 1, wherein the method is used in the treatment of a wound.

### Claim 3 (depends on 2)

A method according to claim 2, wherein the wound is a skin wound.

### Claim 4 (depends on 3)

A method according to claim 3, wherein the wound is a chronic ulcerous skin lesion

### Claim 5 (depends on 4)

A method according to claim 4, wherein the chronic ulcerous skin lesion is selected from venous leg ulcers, venous foot ulcers, arterial leg ulcers, arterial foot ulcers, decubitus ulcers (e.g. pressure sores, bedsores), post-surgical ulcerous lesions and chronic burn lesions.

### Claim 6 (depends on 1)

A method according to claim 1 for inhibiting inflammation and/or the complement cascade and/or the kinin cascade in a wound, for example a chronic ulcerous skin lesion, in a human or non-human mammal, particularly a human, comprising contacting the wound for an effective period of time with a topical hydrogel composition comprising a hydrophilic polymer carrying multiple pendant sulphonyl groups, optionally with multiple pendant carboxylic groups, on each polymer molecule

### Claim 7 (depends on 1)

A method according to claim 1, wherein in the hydrophilic polymer at least some of the pendant groups are present in salt form, so that charge-balancing countercations other than H+ are present in the hydrogel associated with the pendant groups.

### Claim 8 (depends on 7)

A method according to claim 7, wherein two or more different countercations are present in the hydrogel.

### Claim 9 (depends on 8)

A method according to claim 8, wherein the said countercations are selected from relatively weakly hydrated cations according to the Hofmeister series of cations, namely sodium or more weakly hydrated.

### Claim 10 (depends on 9)

A method according to claim 9, wherein the two or more different countercations are selected from sodium, potassium, primary ammonium, secondary ammonium and tertiary ammonium cations.

### Claim 11 (depends on 9)

A method according to claim 9, wherein the countercations are such that the first is the relatively more strongly hydrated according to the Hofmeister series of cations and the second is the relatively more weakly hydrated according to the Hofmeister series of cations.

### Claim 12 (depends on 10)

A method according to claim 10, wherein the first cation is sodium and the second is selected from potassium, primary ammonium, secondary ammonium, tertiary ammonium and quaternary ammonium, or the first is potassium and the second is selected from primary ammonium, secondary ammonium, tertiary ammonium and quaternary ammonium

### Claim 13 (depends on 11)

A method according to claim 11, wherein the molar ratio of the first to the second counterions in the hydrophilic polymer is less than about 250:1, preferably less than about 200:1, for example less than about 100:1, for example less than about 80:1, for example less than about 50:1, and preferably more than about 2:1, for example, between about 2:1 and about 250:1, for example between about 5:1 and about 200:1, for example between about 5:1 and about 100:1, for example between about 7:1 and about 100:1, for example between about 10:1 and about 100:1, the first cation being the relatively more strongly hydrated according to the Hofmeister series of cations and the second being the relatively more weakly hydrated according to the Hofmeister series of cations.

### Claim 14 (depends on 1)

A method according claim 1, wherein the hydrophilic polymer is a homopolymer or copolymer comprising polymerised (co)monomer(s) carrying groups which provide the pendant groups of the polymer.

### Claim 15 (depends on 14)

A method according to claim 14, wherein the monomer or monomers is/are selected from: the sodium salt of 2-acrylamido-2-methylpropane sulphonic acid (NaAMPS); the potassium salt of 2-acrylamido-2-methylpropane sulphonic acid (Potassium AMPS); the ammonium salt of 2-acrylamido-2-methylpropane sulphonic acid (Ammonium AMPS); acrylic acid (3-sulphopropyl) ester potassium salt (SPA or SPAK); acrylic acid (3-sulphopropyl) ester sodium salt (SPANa); SPDA; acrylic acid in partial or complete salt form where the salt counterion is an alkali metal (e.g. sodium or potassium), alkaline earth metal (e.g. calcium) or primary, secondary, tertiary or quaternary ammonium; and any combination or mixture of any two or more of the above.

### Claim 16 (depends on 1)

A method according to any claim 1, wherein the polymer is cross-linked.

### Claim 17 (depends on 8)

A method according to claim 8, wherein the polymer is prepared by polymerising a first monomer in salt form comprising the first countercation and a second monomer, which may be the same as or different from the first monomer, in salt form comprising the second countercation, different from the first countercation.

### Claim 18 (depends on 1)

A method according to claim 1, wherein the hydrogel composition is contacted with the affected location for at least a period in which the value of [TNFα]/[Total Protein] has risen and then fallen to a value the same as or less than the value of [TNFα]/[Total Protein] as measured immediately before the contacting of the hydrogel composition with the affected location, wherein [TNFα] is the mass concentration of TNFα within the wound fluid and [Total Protein] is the mass concentration of the total amount of proteins within the wound fluid, both of which are measured in the same units (for example, g/L).

### Claim 19 (depends on 1)

A method according to claim 1, wherein the hydrogel composition is contacted with the affected location for at least a period in which the value of [TNFα]/[Total Protein] has fallen to a value of 0.5 or less times the value as measured immediately before the contacting of the hydrogel composition with the affected location, wherein [TNFα] is the mass concentration of TNFα within the wound fluid and [Total Protein] is the mass concentration of the total amount of proteins within the wound fluid, both of which are measured in the same units (for example, g/L).

### Claim 20

A hydrogel composition comprising a hydrophilic homopolymer or copolymer carrying multiple pendant sulphonyl groups, optionally with multiple pendant carboxylic groups, the polymer comprising polymerised (co)monomer(s) each carrying groups which provide the pendant groups of the polymer, at least some of the said pendant groups of the polymer being in salt form with a first countercation and a second countercation, different from the first, wherein the said countercations are selected from relatively weakly hydrated cations according to the Hofmeister series of cations and the molar ratio of the said first to the said second countercations in the hydrophilic copolymer is less than about 250:1, preferably less than about 200:1, for example less than about 100:1, for example less than about 80:1, for example less than about 50:1, and preferably more than about 2:1, for example, between about 2:1 and about 250:1, for example between about 5:1 and about 200:1, for example between about 5:1 and about 100:1, for example between about 7:1 and about 100:1, for example between about 10:1 and about 100:1, the first cation being the relatively more strongly hydrated according to the Hofmeister series of cations and the second being the relatively more weakly hydrated according to the Hofmeister series of cations.

### Claim 21 (depends on 20)

A hydrogel composition according to claim 20, wherein the said first and second countercations are selected from sodium, potassium, primary ammonium, secondary ammonium, tertiary ammonium and quaternary ammonium cations.

### Claim 22 (depends on 21)

A hydrogel composition according to claim 21, wherein the first cation is sodium and the second is selected from potassium, primary ammonium, secondary ammonium, tertiary ammonium and quaternary ammonium, or the first is potassium and the second is selected from primary ammonium, secondary ammonium, tertiary ammonium and quaternary ammonium.

### Claim 23 (depends on 20)

A hydrogel composition according to claim 20, for use in the treatment of a wound, for example a chronic skin lesion, in a human or non-human mammal, particularly a human.

### Claim 24

A hydrogel composition for use as an inhibitor of inflammation and/or the complement cascade, particularly in the topical treatment of a wound, for example a chronic skin lesion, in a human or non-human mammal, particularly a human, the hydrogel composition comprising a hydrophilic polymer carrying multiple pendant sulphonyl groups, optionally with multiple pendant carboxylic groups.

### Claim 25

(canceled)

### Claim 26

Use of a hydrogel composition comprising a hydrophilic polymer carrying multiple pendant sulphonyl groups, optionally with multiple pendant carboxylic groups, in the preparation of a topical medicament for use as a protease inhibitor in vivo, particularly in the treatment of a wound, for example a chronic skin lesion, in a human or non-human mammal, particularly a human.

### Claim 27

(canceled)
